Rasna Therapeutics Inc
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to A… Read more
Rasna Therapeutics Inc (RASP) - Total Assets
Latest total assets as of March 2024: $48.61K USD
Based on the latest financial reports, Rasna Therapeutics Inc (RASP) holds total assets worth $48.61K USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rasna Therapeutics Inc - Total Assets Trend (2013–2023)
This chart illustrates how Rasna Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Rasna Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (September 2023)
Rasna Therapeutics Inc's total assets of $48.61K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.4% |
| Accounts Receivable | $20.67K | 21.6% |
| Inventory | $-20.67K | -21.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2023)
This chart illustrates how Rasna Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rasna Therapeutics Inc's current assets represent 100.0% of total assets in 2023, unchanged from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 78.4% of total assets in 2023, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 21.6% of total assets.
Rasna Therapeutics Inc Competitors by Total Assets
Key competitors of Rasna Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Rasna Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Rasna Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Rasna Therapeutics Inc is currently not profitable relative to its asset base.
Rasna Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.03 | 0.05 |
| Quick Ratio | 0.04 | 0.03 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.18 Million | $ -1.87 Million | $ -2.34 Million |
Rasna Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Rasna Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.31 |
| Latest Market Cap to Assets Ratio | 4.03 |
| Asset Growth Rate (YoY) | 12.2% |
| Total Assets | $95.66K |
| Market Capitalization | $385.90K USD |
Valuation Analysis
Premium Asset Valuation: The market values Rasna Therapeutics Inc's assets at a significant premium ( 4.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Rasna Therapeutics Inc's assets grew by 12.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Rasna Therapeutics Inc (2013–2023)
The table below shows the annual total assets of Rasna Therapeutics Inc from 2013 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-09-30 | $95.66K | +12.17% |
| 2022-09-30 | $85.28K | +91.30% |
| 2021-09-30 | $44.58K | +35.31% |
| 2020-09-30 | $32.94K | -99.33% |
| 2019-09-30 | $4.95 Million | -5.35% |
| 2018-09-30 | $5.23 Million | -42.45% |
| 2017-09-30 | $9.08 Million | +3505405.02% |
| 2016-09-30 | $259.00 | -32.73% |
| 2015-09-30 | $385.00 | -94.24% |
| 2014-09-30 | $6.68K | -85.58% |
| 2013-09-30 | $46.34K | -- |